Peiminine

SKU: orb1222594

Description

Peiminine is an effective inhibitor for lung inflammation and pulmonary fibrosis in a rat model of bleomycin-induced lung injury.

Key Properties

• CAS Number: 18059-10-4
• MW: 429.64
• Purity: >98% (HPLC)
• Formula: C₂₇H₄₃NO₃
• SMILES: CC1CCC2C(C3CCC4C(C3CN2C1)CC5C4CC(=O)C6C5(CCC(C6)O)C)(C)O
• Target: EGFR
• Solubility: DMSO : ≥ 100 mg/mL; 232.75 mM

Bioactivity

• In Vivo:
  Animal model: ulcerative colitis model. Dosage: 3 mg/kg. Administration: Intraperitoneal injection (i.p.). Result: Reduced inflammation, mucosal ulcers, involvement of digestive system layers, and infltration of inflammatory cells. Reduced the levels of MPO and NO generated in the rectal tissue. Reduced cell proliferation in spleen cell. Decreased the production of f IL-1β, IL-6, and TNF-α cytokines. Reduced expression levels of genes IL-1β, IL-6, TNF-α, iNOS, and COX2. Animal model: Ovariectomized (OVX) rat model. Dosage: 10 mg/kg. Administration: Intraperitoneal injection (i.p.). Result: Alleviated the bone loss caused by surgical castration. Improved the expression of COL1A1 and β-catenin and reduced the increase expression of PPAR-γ in trabecular bone. Animal model: Allergic dermatitis model. Dosage: 1 mg/kg, 5 mg/kg. Administration: were applied to the dorsal skin. Result: Alleviated the bone loss caused by surgical castration. Improved the expression of COL1A1 and β-catenin and reduced the increase expression of PPAR-γ in trabecular bone.
• In Vitro:
  Cell Cytotoxicity Assay Cell line: HepG2, Hela, SW480, MCF-7. Concentration: 2 μg/mL, 4 μg/mL, 6 μg/mL, 8 μg/mL, 10 μg/mL, 12 μg/mL, and 14 μg/mL. Incubation time: 24 h, 48 h, 72 h. Result: Exhibited a significant inhibition on the survival of HepG2, Hela, SW480 and MCF-7 cells with the IC50 values were 4.58, 4.89, 5.07 and 5.12 μg/mL at 24 h, respectively. Apoptosis Analysis Cell line: HepG2. Concentration: 2 μg/mL, 4 μg/mL, 6 μg/mL, 8 μg/mL. Incubation time: 24 h. Result: Dissociated chromosome to produce DNA fragments dose-dependently. Cell Cycle Analysis Cell line: HepG2. Concentration: 2 μg/mL, 4 μg/mL, 6 μg/mL. Incubation time: 24 h. Result: Decreased the percentage of G1 phases from 65.15% ± 0.78 to 49.55% ± 0.17 with the increase of concentrations. Increased the percentage of G2/M phases from 17.32% ± 0.20 to 39.99% ± 0.47 with the increase of concentrations. Western blot analysis. Cell line: HepG2. Concentration: 2 μg/mL, 4 μg/mL, 6 μg/mL. Incubation time: 24 h. Result: Reduced the expression of procaspase-3, PARP1, procaspases-8 and -9, and Bcl-2 at 2-6 μg/mL.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Verticinone | Raddeanine

Quick Database Links

Gene Symbol

EGFR